Exenatide Response in an Adolescent’s Morbid Obesity
- 1 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 2 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 3 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 4 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 5 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 6 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 7 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 8 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
- 9 Unidad de Diabetes y Obesidad del área VII Murcia Este, Hospital General Universitario Reina Sofía de Murcia,Murcia, España
Abstract
Adolescent obesity is a health problem worldwide. Drug therapy for obesity in children is only acceptable if done within the framework of a comprehensive weight loss, prevention of comorbidities, including health education, changes in lifestyles, diet and exercise. These pharmacological treatments indicate that mainly young patients did not respond to standard measures and developing complications. The role of bariatric surgery, with or without the use of drugs is subject to further research to elucidate its role among the various treatment options for these patients. Currently being studied a wide range of drugs to those included gastrointestinal hormones. Scientific information regarding the use of exenatide in obese patients without diabetes is still limited. The use of exenatide in adolescents with morbid obesity may represent a therapeutic complement invaluable, effective and free of complications, and prevents future bariatric surgery .
- Lamas Piñeyro, R. (2006) Obesity in Children and Adolescents Topics in Pediatrics. Valdés, M.S. and Vasallo, G.A., Eds. Medical Sciences, Havana.
- US Food and Drug Administration (2008) CDER Drug and Biologic Approvals for Calendar Year 2005.
- Buncke, M.C., Diamant, M., Corner, A., Eliasson, B., Malloy, J.L., Shaginian, R.M., et al. (2009) One-Year Treatment with Exenatide Beta-Cell Function Improves, Compare with Insulin Glargine, Metformin in Type 2 Diabetic-Treat Patients: A Randomized, Controlled Trial. Diabetes Care, 32, 762-768. http://dx.doi.org/10.2337/dc08-1797
- Tushuizen, M.E., Buncke, C.M., Pouwels, P.J., van Waesberghe, J.H., Diamant, M. and Heine, R.J. (2006) Incretinmimetics as a Novel Option for Hepatic Steatosis Therapeutic. Liver International, 26, 1015-1017. http://dx.doi.org/10.1111/j.1478-3231.2006.01315.x
- Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Wideload, M.H., Brodows, R.G., et al. (2005) Exenatide versus Insulin Glargine in Suboptimally Controlled Type with Patients 2 Diabetes: A Randomized Trial. Annals of Internal Medicine, 143, 559-569. http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00006